Nasus Pharma Ltd. (NSRX) — Financial Flexibility Index

Latest as of December 2025: -2.19x

Nasus Pharma Ltd. (NSRX) has a Financial Flexibility Index of -2.19x as of December 2025. Free cash flow of $-4.90 Million (operating CF $-4.92 Million minus capex $14.00K) represents -2% of total liabilities ($2.24 Million). Also explore Nasus Pharma Ltd. equity growth rate to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-2.19x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-4.90 Million
Operating CF − Capex

Total Liabilities

$2.24 Million
USD

Capital Expenditures

$14.00K
USD

Nasus Pharma Ltd. Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for Nasus Pharma Ltd. across 4 annual periods. Check NSRX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Annual Financial Flexibility Index for Nasus Pharma Ltd. (2022–2025)

Year-by-year free cash flow to debt coverage for Nasus Pharma Ltd.. For the full company profile including market capitalisation, see Nasus Pharma Ltd. (NSRX) total market value.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -2.19x $-4.90 Million $-4.92 Million $2.24 Million ▼ -1195.8%
2024 -0.17x $-665.00K $-665.00K $3.93 Million ▲ +30.2%
2023 -0.24x $-1.03 Million $-1.03 Million $4.24 Million ▲ +35.8%
2022 -0.38x $-1.21 Million $-1.21 Million $3.20 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities